Record results, raised guidance, and Germany's new platelet safety recommendation? CERS is cooking! 📈 The stock just surged from $1.48 to $1.62 on huge volume, breaking out of its recent slump. RSI is a healthy 55, not overheated, and it's pushing past key moving averages. This news is the real deal, providing the fuel for a sustained move. This is a BUY. The blood is pumping. #Bullish

German regulators are finally catching up to Cerus's blood safety tech! 📈 That's the real story here. The stock's been grinding higher with RSI in a healthy uptrend – not overheated, just steady buying pressure. This feels like the market is slowly pricing in this regulatory tailwind. All signs point to a BUY before the big breakout. #BloodMoney

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Cerus Corporation CERS: 2.07 USD

Bullish views